394 related articles for article (PubMed ID: 27859453)
1. Past, Present, and Future of Antibacterial Economics: Increasing Bacterial Resistance, Limited Antibiotic Pipeline, and Societal Implications.
Luepke KH; Suda KJ; Boucher H; Russo RL; Bonney MW; Hunt TD; Mohr JF
Pharmacotherapy; 2017 Jan; 37(1):71-84. PubMed ID: 27859453
[TBL] [Abstract][Full Text] [Related]
2. The antibiotic pipeline: reviving research and development and speeding drugs to market.
Luepke KH; Mohr JF
Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
[TBL] [Abstract][Full Text] [Related]
3. Effective antibacterials: at what cost? The economics of antibacterial resistance and its control.
White AR;
J Antimicrob Chemother; 2011 Sep; 66(9):1948-53. PubMed ID: 21700625
[TBL] [Abstract][Full Text] [Related]
4. Novel approaches are needed to develop tomorrow's antibacterial therapies.
Spellberg B; Bartlett J; Wunderink R; Gilbert DN
Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
[TBL] [Abstract][Full Text] [Related]
5. Repairing the broken market for antibiotic innovation.
Outterson K; Powers JH; Daniel GW; McClellan MB
Health Aff (Millwood); 2015 Feb; 34(2):277-85. PubMed ID: 25646108
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.
Rex JH; Outterson K
Lancet Infect Dis; 2016 Apr; 16(4):500-5. PubMed ID: 27036356
[TBL] [Abstract][Full Text] [Related]
7. Pull Incentives for Antibacterial Drug Development: An Analysis by the Transatlantic Task Force on Antimicrobial Resistance.
Årdal C; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2017 Oct; 65(8):1378-1382. PubMed ID: 29017240
[TBL] [Abstract][Full Text] [Related]
8. Overcoming the current deadlock in antibiotic research.
Schäberle TF; Hack IM
Trends Microbiol; 2014 Apr; 22(4):165-7. PubMed ID: 24698433
[TBL] [Abstract][Full Text] [Related]
9. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
[TBL] [Abstract][Full Text] [Related]
10. Fighting antibiotic resistance: marrying new financial incentives to meeting public health goals.
Kesselheim AS; Outterson K
Health Aff (Millwood); 2010 Sep; 29(9):1689-96. PubMed ID: 20820028
[TBL] [Abstract][Full Text] [Related]
11. The future of antibiotics.
Spellberg B
Crit Care; 2014 Jun; 18(3):228. PubMed ID: 25043962
[TBL] [Abstract][Full Text] [Related]
12. The global need for effective antibiotics: challenges and recent advances.
Högberg LD; Heddini A; Cars O
Trends Pharmacol Sci; 2010 Nov; 31(11):509-15. PubMed ID: 20843562
[TBL] [Abstract][Full Text] [Related]
13. The global challenge of new classes of antibacterial agents: an industry perspective.
Fernandes P
Curr Opin Pharmacol; 2015 Oct; 24():7-11. PubMed ID: 26119487
[TBL] [Abstract][Full Text] [Related]
14. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
Brogan DM; Mossialos E
Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
[TBL] [Abstract][Full Text] [Related]
15. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps.
Simpkin VL; Renwick MJ; Kelly R; Mossialos E
J Antibiot (Tokyo); 2017 Dec; 70(12):1087-1096. PubMed ID: 29089600
[TBL] [Abstract][Full Text] [Related]
16. Antibiotic research and development: business as usual?
Harbarth S; Theuretzbacher U; Hackett J;
J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
[TBL] [Abstract][Full Text] [Related]
17. Is the GAIN Act a turning point in new antibiotic discovery?
Brown ED
Can J Microbiol; 2013 Mar; 59(3):153-6. PubMed ID: 23540332
[TBL] [Abstract][Full Text] [Related]
18. The crisis of no new antibiotics--what is the way forward?
Piddock LJ
Lancet Infect Dis; 2012 Mar; 12(3):249-53. PubMed ID: 22101066
[TBL] [Abstract][Full Text] [Related]
19. (Inter)nationalising the antibiotic research and development pipeline.
Singer AC; Kirchhelle C; Roberts AP
Lancet Infect Dis; 2020 Feb; 20(2):e54-e62. PubMed ID: 31753765
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]